ECMO–Bridged Versus Elective LVAD Implantation: Comparable Long-Term Survival and Quality of Life in a 13-Year Single-Center Cohort

Background and Objectives: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is an established rescue therapy for refractory cardiogenic shock. When weaning fails, urgent left ventricular assist device (LVAD) implantation under ongoing VA-ECMO support (a bridge-to-bridge strategy) is often the only path to survival. Whether this trajectory compromises long-term outcomes and quality of life (QoL) is unclear. Building on our group’s previous report in a smaller institutional cohort, we now compare long-term survival and QoL between VA-ECMO-bridged and elective LVAD recipients in an expanded cohort with extended follow-up. Materials and Methods: We retrospectively analyzed all adult LVAD implantations at our institution between January 2012 and December 2024. Patients were grouped by urgency: VA-ECMO-bridged (urgent LVAD under ongoing VA-ECMO support) or elective (LVAD without prior mechanical circulatory support). LVAD or mechanical circulatory support device exchanges, post-cardiotomy cardiogenic shock, and pediatric cases were excluded. Survival was analyzed with the Kaplan–Meier method and the log-rank test. Quality of life was assessed prospectively with the EuroQol-5D-5L visual analogue scale and the Patient Health Questionnaire-9 at 3, 6 and 12 months and at the most recent follow-up. Results: Of 97 LVAD recipients, 38 (39%) were VA-ECMO-bridged, and 59 (61%) were electives. The bridged cohort was numerically younger (53.9 ± 14.3 vs. 57.9 ± 11.8 years, p = 0.16), with no difference in sex (78.9% vs. 88.1% male, p = 0.21) or etiology. Intensive care and hospital stays were significantly longer in the bridged group (33.6 vs. 12.6 days, p = 0.029; 58.1 vs. 32.8 days, p = 0.041). Crude mortality at last follow-up was 31.6% (12/38) versus 55.9% (33/59) over 37.5 ± 23.9 vs. 48.8 ± 38.0 months of follow-up; Kaplan–Meier survival did not differ between groups (log-rank p = 0.2310, 95% CI). Quality-of-life questionnaires were completed by 53 of 97 patients (54.6%). EQ-5D-5L visual analogue scale scores improved over the first year in both groups and were equivalent at last follow-up (66.9 ± 20 vs. 65.2 ± 20, p = 0.879); PHQ-9 indicated only mild depressive symptoms in both groups at long-term follow-up (6.0 ± 4.6 vs. 5.4 ± 5.2, p = 0.676). Conclusions: Among patients who survive LVAD implantation, VA-ECMO bridging was not associated with worse long-term survival or quality of life than elective LVAD, despite a markedly longer index hospitalization. This data should be read as showing acceptable outcomes in selected survivors rather than equivalence of an intention-to-bridge strategy, since patients who die on VA-ECMO before LVAD are not captured. Patient selection, rather than urgency itself, appears to drive outcomes.

Authors

Institutions

Publication Details

Journal
Medicina
Published
2026-11-12
DOI
https://doi.org/10.3390/medicina62112213
Primary Topic
Mechanical Circulatory Support Devices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

ECMO–Bridged Versus Elective LVAD Implantation: Comparable Long-Term Survival and Quality of Life in a 13-Year Single-Center Cohort

Christian Schlensak, Rafal Berger, Christoph Salewski, Medhat Radwan et al.
Medicina
Mechanical Circulatory Support Devices
article

ECMO–Bridged Versus Elective LVAD Implantation: Comparable Long-Term Survival and Quality of Life in a 13-Year Single-Center Cohort

Christian Schlensak, Rafal Berger, Christoph Salewski, Medhat Radwan, Spiros Lukas Marinos, Fatos Ballazhi, Isabelle Doll
article en

Abstract

Background and Objectives: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is an established rescue therapy for refractory cardiogenic shock. When weaning fails, urgent left ventricular assist device (LVAD) implantation under ongoing VA-ECMO support (a bridge-to-bridge strategy) is often the only path to survival. Whether this trajectory compromises long-term outcomes and quality of life (QoL) is unclear. Building on our group’s previous report in a smaller institutional cohort, we now compare long-term survival and QoL between VA-ECMO-bridged and elective LVAD recipients in an expanded cohort with extended follow-up. Materials and Methods: We retrospectively analyzed all adult LVAD implantations at our institution between January 2012 and December 2024. Patients were grouped by urgency: VA-ECMO-bridged (urgent LVAD under ongoing VA-ECMO support) or elective (LVAD without prior mechanical circulatory support). LVAD or mechanical circulatory support device exchanges, post-cardiotomy cardiogenic shock, and pediatric cases were excluded. Survival was analyzed with the Kaplan–Meier method and the log-rank test. Quality of life was assessed prospectively with the EuroQol-5D-5L visual analogue scale and the Patient Health Questionnaire-9 at 3, 6 and 12 months and at the most recent follow-up. Results: Of 97 LVAD recipients, 38 (39%) were VA-ECMO-bridged, and 59 (61%) were electives. The bridged cohort was numerically younger (53.9 ± 14.3 vs. 57.9 ± 11.8 years, p = 0.16), with no difference in sex (78.9% vs. 88.1% male, p = 0.21) or etiology. Intensive care and hospital stays were significantly longer in the bridged group (33.6 vs. 12.6 days, p = 0.029; 58.1 vs. 32.8 days, p = 0.041). Crude mortality at last follow-up was 31.6% (12/38) versus 55.9% (33/59) over 37.5 ± 23.9 vs. 48.8 ± 38.0 months of follow-up; Kaplan–Meier survival did not differ between groups (log-rank p = 0.2310, 95% CI). Quality-of-life questionnaires were completed by 53 of 97 patients (54.6%). EQ-5D-5L visual analogue scale scores improved over the first year in both groups and were equivalent at last follow-up (66.9 ± 20 vs. 65.2 ± 20, p = 0.879); PHQ-9 indicated only mild depressive symptoms in both groups at long-term follow-up (6.0 ± 4.6 vs. 5.4 ± 5.2, p = 0.676). Conclusions: Among patients who survive LVAD implantation, VA-ECMO bridging was not associated with worse long-term survival or quality of life than elective LVAD, despite a markedly longer index hospitalization. This data should be read as showing acceptable outcomes in selected survivors rather than equivalence of an intention-to-bridge strategy, since patients who die on VA-ECMO before LVAD are not captured. Patient selection, rather than urgency itself, appears to drive outcomes.

MedicinaVol. 62(11)
Universitätsklinikum Tübingen (DE), University Children's Hospital Tübingen (DE), University of Tübingen (DE)
Good health and well-being
Mechanical Circulatory Support Devices
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon